Autopsy report · NCT05726682

A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

“Sponsor decision to cancel trial, not related to safety concern.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Sanofi

Sponsor type

Industry

Conditions

Allogenic Stem Cell Transplantation

Interventions

SAR445419

Participants

0

Trials that died the same way

• CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)
  “Sponsor decision to not initiate the trial” (85% match in meaning)
• Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
  “Sponsor decision to prematurely stop the study, not linked to any safety concern.” (84% match in meaning)
• A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
  “Sponsor decision not to start trial” (82% match in meaning)
• Phase IIb Clinical Trial of Recombinant Novel Coronavirus Pneumonia (COVID-19) Vaccine (Sf9 Cells)
  “Sponsor decided to cancel this trial.” (82% match in meaning)
• REGENETEN™ Bioinductive Implant System in Full-thickness Tears
  “Sponsor decision not related to safety.” (81% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.